Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
Read the full article on WikipediaRelapsed or chemotherapy refractory Peripheral T-cell Lymphoma Clinical criteria: Treatment Phase: Initial treatment The condition must be relapsed or chemotherapy refractory, AND Patient must have undergone appropriate prior front-line curative intent chemotherapy.
“Pralatrexate is a folate analog metabolic inhibitor designed to selectively enter cancer cells that overexpress the reduced folate carrier (RFC-1). Once inside the cell, pralatrexate competitively inhibits dihydrofolate reductase (DHFR), disrupting folate-dependent processes crucial for DNA synthesis, RNA production, and cell division, ultimately leading to apoptosis. Its enhanced cellular uptake and polyglutamylation contribute to prolonged intracellular retention and potent cytotoxicity, distinguishing it from other antifolate agents.”
Working under the parallel aged-care framework? Aged-care equivalent →